1. Schachat AP, Wilkinson CP, Hinton DR, et al. Ryan's retina: volume 2 medical retina. 6th ed. St. Louis: Elsevier;2017. p. 1038.
2. Klein R, Klein BE, Moss SE, et al. Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984; 91:1464–1474.
3. Csaky KG, Richman EA, Ferris FL 3rd. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2008; 49:479–489.
Article
4. Diabetic Retinopathy Clinical Research Network. Browning DJ, Glassman AR, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology. 2007; 114:525–536.
Article
5. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl):786–806.
6. Domalpally A, Ip MS, Ehrlich JS. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials. Ophthalmology. 2015; 122:779–786.
7. Chew EY, Klein ML, Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol. 1996; 114:1079–1084.
8. Jeon S, Lee WK. Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates. Clin Ophthalmol. 2014; 8:1479–1486.
9. Shin YU, Hong EH, Lim HW, et al. Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections. BMC Ophthalmol. 2017; 17:182.
Article
10. De Benedetto U, Sacconi R, Pierro L, et al. Optical coherence tomographic hyperreflective foci in early stages of diabetic retinopathy. Retina. 2015; 35:449–453.
Article
11. Lammer J, Bolz M, Baumann B, et al. Detection and analysis of hard exudates by polarization-sensitive optical coherence tomography in patients with diabetic maculopathy. Invest Ophthalmol Vis Sci. 2014; 55:1564–1571.
Article
12. Bolz M, Schmidt-Erfurth U, Deak G, et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009; 116:914–920.
13. Niu S, Yu C, Chen Q, et al. Multimodality analysis of hyper-reflective foci and hard exudates in patients with diabetic retinopathy. Sci Rep. 2017; 7:1568.
Article
14. Framme C, Schweizer P, Imesch M, et al. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2012; 53:5814–5818.
Article
15. Ota M, Nishijima K, Sakamoto A, et al. Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment. Ophthalmology. 2010; 117:1996–2002.
Article
16. Lee H, Jang H, Choi YA, et al. Association between soluble CD14 in the aqueous humor and hyperreflective foci on optical coherence tomography in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2018; 59:715–721.
Article
17. Miura M, Makita S, Sugiyama S, et al. Evaluation of intraretinal migration of retinal pigment epithelial cells in age-related macular degeneration using polarimetric imaging. Sci Rep. 2017; 7:3150.
Article
18. Pemp B, Deak G, Prager S, et al. Distribution of intraretinal exudates in diabetic macular edema during anti-vascular endothelial growth factor therapy observed by spectral domain optical coherence tomography and fundus photography. Retina. 2014; 34:2407–2415.
Article
19. Davoudi S, Papavasileiou E, Roohipoor R, et al. Optical coherence tomography characteristics of macular edema and hard exudates and their association with lipid serum levels in type 2 diabetes. Retina. 2016; 36:1622–1629.
Article
20. Sophie R, Lu N, Campochiaro PA. Predictors of functional and anatomic outcomes in patients with diabetic macular edema t reated with ranibizumab. Ophthalmology. 2015; 122:1395–1401.
21. Jenkins AJ, Joglekar MV, Hardikar AA, et al. Biomarkers in diabetic retinopathy. Rev Diabet Stud. 2015; 12:159–195.
Article